Table 2 Hazard ratios with 95% confidence interval for all-cause and disease-specific mortality by tertiles of gamma-glutamyl transferase.

From: Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study

GGT

Model 1

Model 2

Model 3

HR (95% CI)

Total

 

All-cause mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.04 (1.03–1.05)

1.02 (1.01–1.02)

1.05 (1.04–1.05)

  Tertile 3

1.37 (1.36–1.38)

1.30 (1.29–1.31)

1.33 (1.32–1.34)

CVD-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.11 (1.09–1.13)

1.09 (1.07–1.11)

1.07 (1.05–1.09)

  Tertile 3

1.41 (1.39–1.43)

1.37 (1.35–1.39)

1.29 (1.26–1.31)

Cancer-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.09 (1.07–1.10)

1.06 (1.04–1.07)

1.08 (1.07–1.10)

  Tertile 3

1.42 (1.40–1.44)

1.34 (1.32–1.35)

1.38 (1.36–1.39)

Respiratory disease-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

0.99 (0.98–1.02)

0.99 (0.97–1.01)

1.10 (1.08–1.13)

  Tertile 3

1.18 (1.15 -1.21)

1.16 (1.13–1.19)

1.39 (1.35–1.43)

Liver disease-related mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.70 (1.63–1.78)

1.64 (1.57–1.72)

1.74 (1.66–1.83)

  Tertile 3

6.88 (6.61–7.15)

6.21 (5.96–6.46)

6.73 (6.46–7.01)

Men

 

All-cause mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.04 (1.03–1.05)

1.02 (1.01–1.03)

1.07 (1.06–1.08)

  Tertile 3

1.47 (1.46–1.48)

1.39 (1.37–1.40)

1.44 (1.43–1.46)

CVD-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.13 (1.10–1.15)

1.12 (1.09–1.14)

1.09 (1.06–1.11)

  Tertile 3

1.43 (1.40–1.47)

1.41 (1.37–1.44)

1.30 (1.28–1.33)

Cancer-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.12 (1.10–1.14)

1.09 (1.07–1.11)

1.12 (1.11–1.14)

  Tertile 3

1.60 (1.58–1.62)

1.49 (1.47–1.51)

1.54 (1.52–1.57)

Respiratory disease-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

0.99 (0.97–1.02)

0.99 (0.96–1.02)

1.14 (1.11–1.17)

  Tertile 3

1.20 (1.16–1.23)

1.18 (1.15–1.22)

1.44 (1.40–1.49)

Liver disease-related mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.79 (1.65–1.83)

1.68 (1.59–1.77)

1.82 (1.73–1.92)

  Tertile 3

7.61 (7.28–7.96)

6.85 (6.55–7.17)

7.61 (7.27–7.97)

Women

 

All-cause mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

0.97 (0.96–0.98)

0.97 (0.95–0.98)

0.98 (0.96–0.99)

  Tertile 3

1.15 (1.13–1.16)

1.13 (1.12–1.15)

1.13 (1.12–1.15)

CVD-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.00 (0.98–1.03)

0.99 (0.97–1.03)

0.99 (0.96–1.02)

  Tertile 3

1.26 (1.23–1.29)

1.24 (1.21–1.28)

1.21 (1.18–1.25)

Cancer-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.03 (1.00–1.05)

1.02 (1.00–1.05)

1.02 (0.99–1.04)

  Tertile 3

1.19 (1.16–1.22)

1.18 (1.15–1.21)

1.14 (1.12–1.17)

Respiratory disease-specific mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

0.97 (0.93–1.01)

0.97 (0.92–1.01)

1.02 (0.97–1.06)

  Tertile 3

1.12 (1.07–1.16)

1.10 (1.06–1.15)

1.24 (1.18–1.30)

Liver disease-related mortality

  Tertile 1

1(Ref.)

1(Ref.)

1(Ref.)

  Tertile 2

1.37 (1.24–1.51)

1.38 (1.23–1.50)

1.38 (1.25–1.53)

  Tertile 3

4.05 (3.71–4.43)

3.95 (3.62–4.32)

3.98 (3.64–4.36)

  1. PY, person year; CVD, cardiovascular diseases, HR, hazard ratio; CI, confidence interval.
  2. Model 1 was adjusted for age and sex; Model 2 was adjusted for smoking status, alcohol consumption, physical activity, and low income in addition to covariates in model 1; Model 3 was adjusted for body mass index, alanine aminotransferase, diabetes mellitus, hypertension, dyslipidemia, and Charlson comorbidity index score in addition to covariates in model 2.
Back to article page